MyMD Pharmaceuticals Inc MYMD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 08/05/22 EDT
4.36quote price arrow down-0.27 (-5.90%)
Volume
1,325
Close
4.63quote price arrow up+0.21 (+4.75%)
Volume
180,691
52 week range
1.88 - 9.95
Loading...
  • Open4.59
  • Day High4.65
  • Day Low4.33
  • Prev Close4.42
  • 52 Week High9.95
  • 52 Week High Date11/02/21
  • 52 Week Low1.88
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap176.22M
  • Shares Out38.06M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta1.35
  • YTD % Change-23.6

KEY STATS

  • Open4.59
  • Day High4.65
  • Day Low4.33
  • Prev Close4.42
  • 52 Week High9.95
  • 52 Week High Date11/02/21
  • 52 Week Low1.88
  • 52 Week Low Date05/12/22
  • Market Cap176.22M
  • Shares Out38.06M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta1.35
  • YTD % Change-23.6

RATIOS/PROFITABILITY

  • EPS (TTM)-0.84
  • P/E (TTM)-5.48
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-30.502M
  • ROE (TTM)-117.22%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-335.96%
  • Net Margin (TTM)-13,049.39%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On MyMD Pharmaceuticals Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MYMD-1 is a clinical-stage small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MYMD-1 is being developed to treat age-related illnesses, such as...
Joshua Silverman
Lead Independent Director, Chairman of the Board
Chris Chapman M.D.
President, Director, Chief Medical Officer
Ian Rhodes
Interim Chief Financial Officer
Paul Rivard Esq., J.D.
Executive Vice President, General Counsel
Address
855 N. WOLFE STREET, SUITE 623
Baltimore, MD
21205
United States

Top Peers

SYMBOLLASTCHG%CHG
MLSS
Milestone Scientific Inc
1.11UNCHUNCH
ULUR
ULURU Inc
0.1749UNCHUNCH
SINT
SINTX Technologies Inc
0.53+0.0201+3.94%
NBY
NovaBay Pharmaceuticals Inc
0.2809+0.001+0.36%
RMTI
Rockwell Medical Inc
1.60+0.03+1.61%
QIPT
Quipt Home Medical Corp
5.30-0.08-1.49%